• Explore /
  • Poster
  • / A randomized phase III study of duration of anti-PD-1 therapy in metastatic melanoma (STOP-GAP): Canadian Clinical Trials Group study (CCTG) ME.13.

A randomized phase III study of duration of anti-PD-1 therapy in metastatic melanoma (STOP-GAP): Canadian Clinical Trials Group study (CCTG) ME.13.

Abstract Poster

Authors

null

Tara D. Baetz

Division of Medical Oncology, Queen’s University, Kingston, ON, Canada

Tara D. Baetz , Xinni Song , D. Scott Ernst , Elaine McWhirter , Teresa M. Petrella , Kerry J. Savage , Michael Smylie , Ralph Wong , Christopher W Lee , Nicole Look Hong , Diane Logan , Muhammed Saleem Raza , Tahir Abbas , Dora Nomikos , Roger Leung , Bingshu E. Chen , Janet Dancey

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2018 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Melanoma/Skin Cancers

Track

Melanoma/Skin Cancers

Sub Track

Advanced/Metastatic Disease

Clinical Trial Registration Number

NCT02821013.

Citation

J Clin Oncol 36, 2018 (suppl; abstr TPS9600)

DOI

10.1200/JCO.2018.36.15_suppl.TPS9600

Abstract #

TPS9600

Poster Bd #

424b

Abstract Disclosures

Similar Posters

First Author: Inge Marie Svane

Poster

2019 ASCO-SITC Clinical Immuno-Oncology Symposium

Autoimmune toxicities with anti-PD-1 treatment of metastatic melanoma in predominantly older patients: A single institutional experience.

Autoimmune toxicities with anti-PD-1 treatment of metastatic melanoma in predominantly older patients: A single institutional experience.

First Author: Harsh V Parmar

First Author: Daniel Olson

First Author: Joseph McDermott